Cantor Fitzgerald maintains Vertex stock at Overweight, $480 target
Cantor Fitzgerald reiterated its Overweight rating and a $480.00 price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), which currently trades at $438.40 with a market capitalization of ...
Business Insider22d
Vertex Pharmaceuticals (VRTX) Receives a Buy from Cantor Fitzgerald
Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of $480.00. The company’s shares closed ...
ETF Daily News7d
Cantor Fitzgerald Has Weak Outlook for Amgen FY2025 Earnings
Cantor Fitzgerald analyst O. Brayer now forecasts that the medical research company will earn $20.67 per share for the year, down from their previous forecast of $21.44. Cantor Fitzgerald ...
Business Insider15d
Vertex Pharmaceuticals (VRTX) Initiated with a Buy at Cantor Fitzgerald
Vertex Pharmaceuticals (VRTX – Research Report) received a Buy rating and a $480.00 price target from Cantor Fitzgerald analyst Olivia Brayer yesterday. The company’s shares closed yesterday ...
Investing3d
Cantor Fitzgerald maintains Vertex stock Overweight rating
Tuesday, Cantor Fitzgerald reaffirmed its Overweight rating on Vertex ... with analyst targets ranging from $330 to $615. The firm's analyst, Olivia Brayer, provided insights into the pharmaceutical ...